On one hand, the reduction of PGE2 significantly downregulates the PD-L1 expression of tumor cells and myeloid cells, thereby blocking the inhibitory effect of PD-1/PD-L1 immune checkpoints on T cells (Cecil et al., 2022; Rao, 2022). The gene discussed is PDCD1; the disease is neoplasm.